Evidence map›Paper›PMID 34832907›Full record

ReviewPharmaceuticals (Basel, Switzerland)2021

Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis.

Everton M da Silva, Hérika D A Vidal, Arlene G Corrêa

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Everton M da SilvaCentre of Excellence for Research on Sustainable Chemistry, Department of Chemistry, Federal University of São Carlos, São Carlos 13565-905, SP, Brazil.ORCID 0000-0003-4346-1803
Hérika D A VidalCentre of Excellence for Research on Sustainable Chemistry, Department of Chemistry, Federal University of São Carlos, São Carlos 13565-905, SP, Brazil.ORCID 0000-0002-9483-3411
Arlene G CorrêaCentre of Excellence for Research on Sustainable Chemistry, Department of Chemistry, Federal University of São Carlos, São Carlos 13565-905, SP, Brazil.ORCID 0000-0003-4247-2228

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance Code 001GlaxoSmithKline (United Kingdom) 0National Council for Scientific and Technological Development 302140/2019-0National Council for Scientific and Technological Development 429748/2018-3São Paulo Research Foundation 2013/07600-3São Paulo Research Foundation 2014/50249-8
6 · The paper itself

Abstract

Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods.

Indexed as

antiviralsasymmetric synthesisgreen chemistryorganocatalysisselectivity

Identifiers

PMID34832907
PMCPMC8625736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.